Note 8 - Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2018

Notes Tables

Reconciliation of Revenue from Segments to Consolidated [Table Text Block]

	Three Months Ended March 31, 2018
	Clinical Development			Device			Total
Net revenues	$	62,000		$	1,805,000		$	1,867,000
Cost of revenues		71,000			1,444,000			1,515,000
Gross profit		(9,000	)		361,000			352,000
Operating expenses		1,179,000			2,429,000			3,608,000
Operating loss	$	(1,188,000	)	$	(2,068,000	)	$	(3,256,000	)
Depreciation and amortization	$	68,000		$	91,000		$	159,000
Stock-based compensation expense	$	98,000		$	39,000		$	137,000
Goodwill	$	13,195,000		$	781,000		$	13,976,000
Total assets	$	38,941,000		$	11,240,000		$	50,181,000

	Three Months Ended March 31, 2017
	Clinical Development			Device			Total
Net revenues	$	153,000		$	3,099,000		$	3,252,000
Cost of revenues		124,000			1,751,000			1,875,000
Gross profit		29,000			1,348,000			1,377,000
Operating expenses		1,934,000			1,559,000			3,493,000
Operating loss	$	(1,905,000	)	$	(211,000	)	$	(2,116,000	)
Depreciation and amortization	$	116,000		$	69,000		$	185,000
Stock-based compensation expense	$	151,000		$	96,000		$	247,000